Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin 2020;70:7–30. https://doi.org/10.3322/caac.21590.
Lester, 2016
Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI: J Natl Cancer Inst 2014;106. https://doi.org/10.1093/jnci/dju055.
Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol 2018;10:175883591878645. https://doi.org/10.1177/1758835918786451.
Robson, 2017, Olaparib for metastatic breast cancer in patients with a germline BRCA mutation, N Engl J Med, 377, 523, 10.1056/NEJMoa1706450
Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther 2017;4. https://doi.org/10.15761/ICST.1000228.
Győrffy, 2015, Multigene prognostic tests in breast cancer: past, present, future, Breast Cancer Res, 17, 11, 10.1186/s13058-015-0514-2
Samaan, 1981, Estrogen receptor: a prognostic factor in breast cancer, Cancer, 47, 554, 10.1002/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W
Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106
Gyorffy, 2009, Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples, PLoS ONE, 4, e5645, 10.1371/journal.pone.0005645
Fekete, 2012, Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples, Int J Cancer, 131, 95, 10.1002/ijc.26364
Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303
Mihály, 2013, Improving pathological assessment of breast cancer by employing array-based transcriptome analysis, Microarrays (Basel), 2, 228, 10.3390/microarrays2030228
Huang, 2009, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nat Protoc, 4, 44, 10.1038/nprot.2008.211
Györffy, 2010, An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients, Breast Cancer Res Treat, 123, 725, 10.1007/s10549-009-0674-9
Li, 2011, Jetset: selecting the optimal microarray probe set to represent a gene, BMC Bioinf, 12, 474, 10.1186/1471-2105-12-474
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432–44. https://doi.org/10.1016/S0140-6736(11)61625-5.
Dickens, 2018, Principles of cancer treatment by chemotherapy, Surgery (Oxford), 36, 134, 10.1016/j.mpsur.2017.12.002
Wagner, 2020, Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx, J Clin Oncol, 38, 1875, 10.1200/JCO.19.01866
Mihály, 2013, A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer, Breast Cancer Res Treat, 140, 219, 10.1007/s10549-013-2622-y
Sparano, 2019, Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer, N Engl J Med, 380, 2395, 10.1056/NEJMoa1904819
Sparano, 2018, Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, N Engl J Med, 379, 111, 10.1056/NEJMoa1804710
Almstedt, 2020, EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer, Breast Cancer Res Treat, 182, 137, 10.1007/s10549-020-05688-1
Mitchison, 2012, The proliferation rate paradox in antimitotic chemotherapy, Mol Biol Cell, 23, 1, 10.1091/mbc.e10-04-0335
Bertucci, 2012, Basal breast cancer: a complex and deadly molecular subtype, Curr Mol Med, 12, 96, 10.2174/156652412798376134
Bianchini, 2010, Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers, J Clin Oncol, 28, 4316, 10.1200/JCO.2009.27.2419
Lehmann, 2016, Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection, PLoS ONE, 11, e0157368, 10.1371/journal.pone.0157368
Pusztai, 2016, New strategies in breast cancer: immunotherapy, Clin Cancer Res, 22, 2105, 10.1158/1078-0432.CCR-15-1315
Tegze, 2012, Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance, PLoS ONE, 7, e30804, 10.1371/journal.pone.0030804
Coates, 2015, Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Ann Oncol, 26, 1533, 10.1093/annonc/mdv221
Fletcher, 2010, ABC transporters in cancer: more than just drug efflux pumps, Nat Rev Cancer, 10, 147, 10.1038/nrc2789
Fujiki, 2018, APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer, Oncotarget, 9, 30513, 10.18632/oncotarget.25495
Nguyen, 2020, Association of independent prognostic factors and treatment modality with survival and recurrence outcomes in breast cancer, JAMA Netw Open, 3, e207213, 10.1001/jamanetworkopen.2020.7213
Munkácsy, 2010, PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer, Br J Cancer, 102, 361, 10.1038/sj.bjc.6605478